# Medical Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sun Yat-sen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET016-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Raymond Choi, MD
- Calendar frame: modern shifted

- Requested by: Wen-Li Huang, MD

## Reason for consultation

A solid 6.8 cm mass in liver segments IV and V, inseparable from a gallbladder containing stones, in a 57-year-old man with three months of right upper abdominal aching, early fullness and 4 kg weight loss. He trained and briefly practiced as a physician. Multiphase CT, tumor markers and hepatitis serology are under way. Please establish the diagnosis, stage the disease, take him to the tumor board, and advise on treatment. **S**

## History

Mr. Sun, a 57-year-old political leader who trained and briefly practiced in medicine, is seen at the request of Dr. Huang two weeks after presenting with three months of right upper abdominal aching, early fullness and 4 kg weight loss and a palpable mass. He has had a multiphase CT, MRI with MRCP and an ultrasound-guided core biopsy. He has no jaundice, itching, fever or vomiting, and works full days. He reviewed the images with us and asked for a plain account. **S**

## Examination

| System | Finding |
|---|---|
| General | Thin, alert, no jaundice; blood pressure 128/82, pulse 86; ECOG 1 |
| Abdomen | Firm, non-tender mass 4 cm below the right costal margin, moving with breathing; no ascites |
| Lymph nodes | No supraclavicular or umbilical nodes |

BP 128/82 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 60.6 kg; BMI 22.3 kg/m². All vital signs are synthetic.

## Data reviewed

Multiphase CT of the liver with CT of the chest, abdomen and pelvis: a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, gallstones, two enlarged hepatoduodenal ligament nodes (1.6 and 1.3 cm), main portal vein and hepatic artery free, no other liver lesions, no ascites, a 6 mm calcified granuloma in the right upper lobe. MRI with MRCP: the mass arises from the gallbladder wall; no bile duct dilation; liver smooth without cirrhosis. Core biopsy: moderately differentiated adenocarcinoma, CK7 positive, CK20 and CDX2 negative. Alpha-fetoprotein 3.2 ng/mL, CA 19-9 412 U/mL, CEA 8.6 ng/mL. Albumin 3.4 g/dL, bilirubin 0.9 mg/dL, INR 1.0, creatinine 0.86 mg/dL. Hepatitis B surface antigen negative, core antibody positive, surface antibody 85 mIU/mL, HBV DNA undetectable; hepatitis C antibody negative. ECOG performance status: 1. All results are synthetic.

## Assessment

1. **Adenocarcinoma of the gallbladder invading the liver** (C23). This is not a primary liver cancer. In a liver without cirrhosis the imaging criteria for hepatocellular carcinoma do not apply and tissue is needed; the biopsy shows an adenocarcinoma with a pancreatobiliary pattern, the imaging shows it arising from the gallbladder wall, and alpha-fetoprotein is normal. This is a primary gallbladder adenocarcinoma invading the liver, clinical T3 N1 M0 (stage IIIB) on imaging. Gallbladder cancer often has peritoneal spread that CT does not show, so a staging laparoscopy should come before any attempt at resection. If there is no metastatic disease, an extended cholecystectomy with resection of segments IVb and V and portal lymphadenectomy could be curative in intent; if there is, treatment is systemic: gemcitabine and cisplatin with durvalumab is the preferred first-line regimen. Genomic profiling of the biopsy now will save time if a targeted treatment becomes relevant. **S**
2. **Resolved hepatitis B infection** (Z86.19). Resolved past infection with undetectable HBV DNA and preserved liver function (Child-Pugh A6, ALBI grade 2). It does not limit surgery or chemotherapy. The reactivation risk with gemcitabine, cisplatin and durvalumab is low to moderate; monitoring HBV DNA and ALT every 3 months, with entecavir if HBV DNA becomes detectable, is appropriate. Hepatitis C is excluded. **S**

## Recommendations

1. Multidisciplinary hepatobiliary tumor board review this week.
2. Staging laparoscopy before any resection, with biopsy of any peritoneal disease and an implanted port placed under the same anesthetic.
3. If there are no metastases: extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy, then adjuvant treatment; if there are metastases: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab every 4 weeks.
4. Comprehensive genomic profiling of the biopsy tissue now (HER2, mismatch repair and microsatellite status, FGFR2, IDH1, BRAF, NTRK, RET, KRAS, tumor mutational burden).
5. HBV DNA and ALT every 3 months during treatment and for 6 to 12 months after, with entecavir if HBV DNA becomes detectable or surface antigen reappears.
6. Specialist palliative care alongside treatment as soon as advanced disease is confirmed, or earlier if he wishes.
7. Results shared with him in full and in person, with his images, by one coordinating clinician; the same pathway and the same thresholds as for any patient.

## Strengths and supports

- Strengths and supports: a clear, analytical mind and his own medical training; a strong sense of purpose in his work; a wide circle of colleagues **S**

## Communication

Discussed with Dr. Huang, who sees him the same day. Mr. Sun reviewed the images and the pathology with us. We explained why a staging laparoscopy comes before any operation, what each result would mean for treatment, and that the aim of treatment would be decided by that result. He asked to hear results himself first and to decide who else is told; he agreed to the plan. He decides who receives this note. **S**

## Follow-up

Tumor board this week; staging laparoscopy in about ten days; review with Dr. Huang and the oncology team in two weeks with the result to decide treatment. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026), National Comprehensive Cancer Network
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology)
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022), NEJM Evidence
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)
